Works matching AU Palandri, Francesca
Results: 97
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 241, doi. 10.1007/s00277-025-06204-5
- By:
- Publication type:
- Article
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00834-6
- By:
- Publication type:
- Article
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Long-term follow-up of recovered MPN patients with COVID-19.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00392-1
- By:
- Publication type:
- Article
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.
- Published in:
- Frontiers in Oncology, 2019, v. 9, p. 1, doi. 10.3389/fonc.2019.01186
- By:
- Publication type:
- Article
MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S362, doi. 10.1016/S2152-2650(21)01833-4
- By:
- Publication type:
- Article
Poster: MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S234, doi. 10.1016/S2152-2650(21)01477-4
- By:
- Publication type:
- Article
Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S354, doi. 10.1016/j.clml.2017.07.183
- By:
- Publication type:
- Article
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 2775, doi. 10.1007/s00277-024-05867-w
- By:
- Publication type:
- Article
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 7, p. 2347, doi. 10.1007/s00277-024-05809-6
- By:
- Publication type:
- Article
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 2, p. 437, doi. 10.1007/s00277-023-05577-9
- By:
- Publication type:
- Article
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 5, p. 963, doi. 10.1007/s00277-022-04786-y
- By:
- Publication type:
- Article
Is there a gender effect in polycythemia vera?
- Published in:
- Annals of Hematology, 2021, v. 100, n. 1, p. 11, doi. 10.1007/s00277-020-04287-w
- By:
- Publication type:
- Article
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Treating early-stage myelofibrosis.
- Published in:
- Annals of Hematology, 2019, v. 98, n. 2, p. 241, doi. 10.1007/s00277-018-3526-z
- By:
- Publication type:
- Article
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
- Published in:
- 2015
- By:
- Publication type:
- Letter
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis.
- Published in:
- 2015
- By:
- Publication type:
- Letter
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.
- Published in:
- Annals of Hematology, 2013, v. 92, n. 1, p. 67, doi. 10.1007/s00277-012-1556-5
- By:
- Publication type:
- Article
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.
- Published in:
- Annals of Hematology, 2011, v. 90, n. 8, p. 933, doi. 10.1007/s00277-010-1154-3
- By:
- Publication type:
- Article
The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report.
- Published in:
- Hematology Reports, 2021, v. 13, n. 2, p. 1, doi. 10.4081/hr.2021.8814
- By:
- Publication type:
- Article
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2021, v. 40, n. 1, p. 1, doi. 10.1186/s13046-020-01776-8
- By:
- Publication type:
- Article
Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34<sup>+</sup> Cells.
- Published in:
- Mediators of Inflammation, 2018, p. 1, doi. 10.1155/2018/5974613
- By:
- Publication type:
- Article
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 9, p. 4089, doi. 10.1002/cam4.2107
- By:
- Publication type:
- Article
The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 9, p. 2316, doi. 10.3390/cells10092316
- By:
- Publication type:
- Article
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/20406207211048361
- By:
- Publication type:
- Article
The "Vesicular Intelligence" Strategy of Blood Cancers.
- Published in:
- Genes, 2021, v. 12, n. 3, p. 416, doi. 10.3390/genes12030416
- By:
- Publication type:
- Article
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 987, doi. 10.1111/bjh.15682
- By:
- Publication type:
- Article
Understanding how older age drives decision‐making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 3, p. 424, doi. 10.1111/bjh.15668
- By:
- Publication type:
- Article
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 1, p. 35, doi. 10.1111/bjh.15497
- By:
- Publication type:
- Article
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 1, p. 160, doi. 10.1111/bjh.13758
- By:
- Publication type:
- Article
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 5, p. 729, doi. 10.1111/bjh.13324
- By:
- Publication type:
- Article
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 4, p. 541, doi. 10.1111/bjh.13080
- By:
- Publication type:
- Article
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 1, p. 142, doi. 10.1111/bjh.12186
- By:
- Publication type:
- Article
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years.
- Published in:
- British Journal of Haematology, 2012, v. 156, n. 5, p. 676, doi. 10.1111/j.1365-2141.2011.08903.x
- By:
- Publication type:
- Article
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients.
- Published in:
- British Journal of Haematology, 2012, v. 156, n. 2, p. 281, doi. 10.1111/j.1365-2141.2011.08858.x
- By:
- Publication type:
- Article
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 1, p. 123, doi. 10.1002/hon.2808
- By:
- Publication type:
- Article
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Comparison of JAK2<sup>V617F</sup> -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Impact of Red Blood Cell Transfusions on Quality of Life for Patients With Myelofibrosis in the SIMPLIFY-1 and SIMPLIFY-2 Clinical Trials.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 357
- By:
- Publication type:
- Article
Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly.
- Published in:
- Mediators of Inflammation, 2016, p. 1, doi. 10.1155/2016/5860657
- By:
- Publication type:
- Article